ARCT-021

ARCT-021
Vaccine description
Target	SARS-CoV-2
Vaccine type	mRNA
Clinical data
Other names	LUNAR-COV19
Routes of; administration	Intramuscular

ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

Medical uses[]

It requires the intramuscular injection with a single dose.^[1]

Pharmacology[]

ARCT-021 is an mRNA vaccine.^[2]

History[]

Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.^[3] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.^[4]

Clinical trials[]

LUNAR-COV19 clinical trials in humans began in July 2020.^[5] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.^[6]

Economics[]

Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.^[7]^[8]

References[]

^ "Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data". Businesswire. 10 May 2021. Retrieved 9 September 2021.
^ "Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". Globe Newswire. 11 August 2020.
^ Teo J (15 April 2020). "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.
^ Stanton D (6 May 2020). "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. Retrieved 8 May 2020.
^ Clinical trial number NCT04480957 for "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects" at ClinicalTrials.gov
^ "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.
^ Anwar N (26 November 2020). "Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021". CNBC. Retrieved 18 March 2021.
^ Cheok M, Mookerjee I (5 August 2020). "Singapore Will Get First Claim to Any Successful Arcturus Vaccine". Bloomberg. Retrieved 18 March 2021.

External links[]

Scholia has a profile for Lunar-COV19 (Q98713328).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by .

This article about vaccines or vaccination is a stub. You can help Wikipedia by .

[1] "Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data". Businesswire. 10 May 2021. Retrieved 9 September 2021.

[2] "Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". Globe Newswire. 11 August 2020.

[3] Teo J (15 April 2020). "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.

[4] Stanton D (6 May 2020). "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. Retrieved 8 May 2020.

[5] Clinical trial number NCT04480957 for "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects" at ClinicalTrials.gov

[6] "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.

[7] Anwar N (26 November 2020). "Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021". CNBC. Retrieved 18 March 2021.

[8] Cheok M, Mookerjee I (5 August 2020). "Singapore Will Get First Claim to Any Successful Arcturus Vaccine". Bloomberg. Retrieved 18 March 2021.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments China US Fake treatments Protests US Software Travel restrictions United Nations World Health Organization WTO IP waiver Undercounting of deaths Zero-COVID National responses Africa China European Union Germany Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Vaccine candidates CoronaVac Covaxin Convidecia Janssen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Canadian meat US meat Food security Journalism Music Performing arts Retail Shipping Sports Ireland Philippines Television US programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US
Impacts Animals Black people Crime Ireland Death rates by country Disability Domestic violence Emergency evacuations Education Female Ghana Ireland UK US Environment Hospitals Language LGBT community Long-term care Mental health Symptoms Migration Military Notable deaths South Africa Other health issues Politics Ireland Malaysia Russia Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Society Ireland Malaysia New Zealand Russia UK US Strikes Suicides Telehealth Xenophobia and racism
COVID-19 portal
v t